77611-51-9

Usage

Uses

Used in Pharmaceutical Industry:
4,4,4-trifluoro-1-thiophen-3-yl-butane-1,3-dione is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to enhance the electron-withdrawing characteristics of the final products, thereby potentially improving their therapeutic efficacy.
Used in Agrochemical Industry:
In the agrochemical sector, 4,4,4-trifluoro-1-thiophen-3-yl-butane-1,3-dione is utilized as an intermediate in the production of agrochemicals, where its electron-withdrawing properties can contribute to the effectiveness of pesticides and other agricultural chemicals.
Used in Organic Synthesis:
4,4,4-trifluoro-1-thiophen-3-yl-butane-1,3-dione is employed as a versatile building block in organic synthesis, allowing for the creation of a wide range of chemical compounds with diverse applications.
Used in Biological Research:
Due to its potential biological activity, 4,4,4-trifluoro-1-thiophen-3-yl-butane-1,3-dione is used in research for its anti-inflammatory and anti-cancer properties, with the aim of discovering new therapeutic agents.

InChI:InChI=1/C8H5F3O2S/c9-8(10,11)7(13)3-6(12)5-1-2-14-4-5/h1-2,4H,3H2

Upstream product

• 1468-83-3 1-(thiophen-3-yl)-ethanone 
• 383-63-1 ethyl trifluoroacetate, 
• 407-38-5 2,2,2-trifluoroethyl trifluoroacetate 

Relevant academic research and scientific papers

A Sequential Route to Cyclopentenes from 1,6-Enynes and Diazo Ketones through Gold and Rhodium Catalysis

This work reports the construction of cyclopentene cores from 1,6-enynes and aryl diazo ketones through two new reaction sequences involving initial gold-catalyzed cyclization of 1,6-enynes with diazo species, followed by rhodium-catalyzed skeletal rearrangement of the resulting 3-cyclopropyl-2-en-1-ones. In most instances the rhodium-catalyzed reactions afforded cyclopentene derivatives whereas several n-alkyl- or ortho-substituted phenyl ketones delivered seven-membered oxacycles. A plausible mechanism provides rationales for these two distinct products. (Figure presented.).

Synthesis and SAR/3D-QSAR studies on the COX-2 inhibitory activity of 1,5-diarylpyrazoles to validate the modified pharmacophore

Diverse analogs of 1,5-diarylpyrazoles having 3-hydroxymethyl-4-sulfamoyl (SO2NH2)/methyl sulfonyl (SO2Me)-pheny group at N1 were synthesized and evaluated for their in vitro cyclooxygenase (COX-1/COX-2) inhibitory activity. The SAR study mainly involved the variations at positions C-3, C-5 and N1 of the pyrazole ring. Several small hydrophobic groups at/around position-4 of C-5 phenyl, viz. 3,4-dimethylphenyl analog 9, 3-methyl-4-methylsulfanylphenyl analog 14 and 2,3-dihydrobenzo[b] thiophenyl analog 17, exhibited impressive COX-2 inhibitory potency. In general, the sulfonamide analogues with a CHF2 at C-3 were found to be more potent than those having a CF3 group. The three dimensional quantitative structure activity relationship comprising comparative molecular field analysis (3D-QSAR-CoMFA) afforded the models with high predictivity which further validated the acceptance of hydroxymethyl (CH2OH) group in the hydrophilic pocket of the COX-2 enzyme.

Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. Part 4: Heterocycles at C3

New indeno[1,2-c]pyrazol-4-one cyclin dependent kinase inhibitors have been disclosed. The most promising compounds are nanomolar enzyme inhibitors with excellent activity against tumor cells. The most advanced compound retains cell culture activity even in the presence of human serum proteins. The most advanced compound did not kill the normal fibroblast line AG1523.